艾滋病药物绥美凯上市了吗
It is currently the only three-in-one compound drug containing dolutegravir (DTG). It integrates therapeutic drugs for different stages of viral infection into the same tablet, one tablet at a time, and has the characteristics of high efficiency, good tolerance, high resistance barrier, and few drug interactions. So is it on the market?
On January 22, 2018, Inbec was launched in China and is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.
Inbec is suitable for adults and adolescents over 12 years old and weighing no less than 40kg. Since the ingredients in Inbec may cause hypersensitivity reactions, patients should be screened for HLA-B*5701 alleles before starting treatment with abacavir-containing products, regardless of race.
The recommended dosage of Inbec is one tablet, once daily. Adults or adolescents whose weight is less than 40kg should not be given Inbec because Inbec is a fixed-dose tablet and the dose cannot be reduced. Reducing the dose without authorization may result in the inefficiency of the drug. Clinical data on Inbec are limited, and the most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacalongvir/lamivudine are nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).
Very rarely, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis may occur, and abacavir hypersensitivity cannot be excluded. In such cases, abacavir-containing medicinal products should be permanently discontinued. In individual patients, hypersensitivity reactions, including rash and severe hepatic effects, may occur. If patients experience mild side effects, don’t worry too much. They will generally subside over time. Once serious side effects occur, everyone must pay attention and seek medical treatment in time. Don’t be careless.
Recommended related hot articles: /newsDetail/80771.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)